ARBITER 3 Trial

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

ARBITER 3 Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of ARBITER 3 Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ARBITER 3 Trial

CDC on ARBITER 3 Trial

ARBITER 3 Trial in the news

Blogs on ARBITER 3 Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for ARBITER 3 Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Objective

[edit | edit source]

To study the effects of long term treatment with extended release niacin (ERN) on HDL levels and carotid intima- media thickness in patients who participated in ARBITER 2.

## Methods

[edit | edit source]

88% (149) of patients enrolled in the ARBITER trial participated in the ARBITER 3 trial, those who either were continued or crossed over to the placebo group. The long term effects of ERN on HDL cholesterol and carotid intima- media thickness were examined during 12- 24 months of treatment.

## Results

[edit | edit source]

* The ERN group showed an increase in HDL-C levels along with modest reductions in LDL-C and triglycerides.
* A net regression in CMIT was seen in patients treated with ENC for 12 months.
* An additional regression was noted in patients treated with ENC for 24 months.
* Changes in HDL-C were independently associated with regression of CIMT, controlling for changes in LDL and triglycerides.

## Conclusion

[edit | edit source]

ERN when added to statin therapy significantly increases HDL levels and induces atherosclerosis regression. Open label design and the inability to correlate CIMT effects to clinical outcomes were the limitations of this study.[1]

## References

[edit | edit source]

1. ↑ Taylor AJ, Lee HJ, Sullenberger LE (2006). "The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3". Current Medical Research and Opinion. 22 (11): 2243–50. doi:10.1185/030079906X148508. PMID 17076985. Unknown parameter `|month=` ignored (help)CS1 maint: Multiple names: authors list (link)

* v
* t
* e

Lipopedia

Basic Science|

Cholesterol • Triglyceride

Lipoprotein metabolism and transport

Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X

Apolipoprotein: APOA (1, 2, 4,  5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a)

Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor

Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1

Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1

Lipoprotein Disorders|

Lipoprotein disorders

Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V)

Secondary lipoprotein disorders

Abnormal Laboratory Lipid Profile|

Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL

High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template